Ex vivo and in vivo IGF-I antisense RNA strategies for treatment of cancer in humans.

摘要: Two technical approaches to gene therapy for cancer utilize ex vivo and in transfer methodology. This paper focuses on applicability use of each these using an IGF-I antisense RNA strategy treatment. Insulin-like growth factor I (IGF-I) IGF-II have pivotal roles cell proliferation development (for review see 1–4). The preponderance peptide synthesis activity occur during fetal development. Protein is down-regulated most mature tissues except adult liver. However, many cancers produce secrete and/or also express receptor. These include: astrocytomas, glioblastoma multiforme, sarcomas, thyroid adenomas, hepatocellular cancer, small the lung, carcinomas breast, colon, prostate gland. initiation early tumors may be dependent upon changes mitogenic peptides or their receptors. Kaleko et. al. (1990) showed that overexpression human receptor mice fibroblasts promotes colony formation soft agar cells grown 10% serum supplemented with IGF-I. Trojan, Ilan, colleagues demonstrated 1992 inhibition expression by inhibits tumor causes regression cure wild-type C6 rats (6). They further was infiltrated CD8 lymphocytes as process resolved, suggesting treatment act through immunogenic mechanism (7). Resnicoff, Baserga, down-regulation rat prevents induced wild type (8–9).